Combination therapies in ophthalmology: Implications for intravitreal delivery

Journal of Ophthalmic and Vision Research

Volumn 6, Issue 1, 2011, Pages 36-46

  Peyman, Gholam A ^a,b   Hosseini, Kamran ^c  

^a UNIVERSITY OF ARIZONA   (United States)

^b TULANE UNIVERSITY   (United States)

^c InSite Vision Inc   (United States)

Author keywords

Combination therapy; Combined modality therapy; Intravitreal delivery

Indexed keywords

EID: 79951562720     PISSN: 20082010     EISSN: 2008322X     Source Type: Journal    
DOI: None     Document Type: Review

References (59)

1. Broukhim M, Halperin JL. Stroke prevention in the high-risk atrial fibrillation patient: medical management. Curr Cardiol Rep 2010. [Epub ahead of print]
2. Kuno N, Fujii S. Biodegradable intraocular therapies for retinal disorders: progress to date. Drugs Aging 2010;27:117-134.
3. Minkowitz HS, Yarmush J, Donnell MT, Tonner PH, Damaraju CV, Skowronski RJ. Safety and tolerability of fentanyl iontophoretic transdermal system: findings from a pooled data analysis of four clinical trials. J Opioid Manag 2010;6:203-210.
4. Wu P, Grainger DW. Review of drug/device combinations for local drug therapies and infection prophylaxis. Biomaterials 2006;27:2450-2467.
5. Heilmann K. A report on Ocusert. Klin Monbl Augenheilkd 1975;167:534-542.
6. Tao W. Application of encapsulated cell technology for retinal degenerative diseases. Expert Opin Biol Ther 2006;6:717-726.
7. Chang-Lin JE, Attar M, Acheampong AA, Robinson MR, Whitcup SM, Kuppermann B, et al. Pharmacokinetics and pharmacodynamics of the sustained-release dexamethasone intravitreal implant. Invest Ophthalmol Vis Sci 2010. [Epub ahead of print]
8. Peyman GA, Cormier MJN, Hosseini K. Intravitreal injection device, system and method. United States Patent 7678078.
9. White CJ, Byrne ME. Molecularly imprinted therapeutic contact lenses. Expert Opin Drug Deliv 2010;7:765-780.
10. Kim J, Peng CC, Chauhan A. Extended release of dexamethasone from silicone-hydrogel contact lenses containing vitamin E. J Control Release 2010. [Epub ahead of print]
11. Helzinger J. Toward better delivery of glaucoma meds. Ophthalmology Management 2010;4.
12. Peng YJ, Kau YC, Wen CW, Liu KS, Liu SJ. Solvent-free biodegradable scleral plugs providing sustained release of vancomycin, amikacin, and dexamethasone- an in vivo study. J Biomed Mater Res A 2010;94:426-432.
13. Messmer KJ, Abel SR. Verteporfin for agerelated macular degeneration. Ann Pharmacother 2001;35:1593-1598.
14. Roth DB, Flynn HW Jr. Antibiotic selection in the treatment of endophthalmitis: the significance of drug combinations and synergy. Surv Ophthalmol 1997;41:395-401.
15. Peyman GA, Vastine DW, Crouch ER, Herbst RW Jr. Clinical use of intravitreal antibiotics to treat bacterial endophthalmitis. Trans Am Acad Ophthalmol Otolaryngol 1974;78:862-875.
16. Peyman GA, Spitznas M, Straatsma BR. Chorioretinal diffusion of peroxidase before and after photocoagulation. Invest Ophthalmol 1971;10:489-495.
17. Newton DW. Drug Incompatibility Chemistry. Am J Health-Syst Pharm 2009;66:348-357.
18. Newton DW. Introduction. In: Trissel LA (ed). Handbook on Injectable Drugs. 3rd ed. Bethesda: American Society of Hospital Pharmacists Inc; 1983: xi-xxi.
19. Nevyas AS, Raber IM, Eagle RC Jr, Wallace IB, Nevyas HJ. Acute band keratopathy following intracameral Viscoat. Arch Ophthalmol 1987;105:958-964.
20. Jensen MK, Crandall AS, Mamalis N, Olson RJ. Crystallization on intraocular lens surfaces associated with the use of Healon GV. Arch Ophthalmol 1994;112:1037-1042.
21. Ward C, Weck S. Dilution and storage of recombinant tissue plasminogen activator (Activase) in balanced salt solutions. Am J Ophthalmol 1990;109:98-99.
22. Wilhelmus KR, Abshire RL. Corneal ciprofloxacin precipitation during bacterial keratitis. Am J Ophthalmol 2003;136:1032-1037.
23. Hui M, Kwok AK, Pang CP, Cheung SW, Chan RC, Lam DS, et al. An in vitro study on the compatibility and precipitation of a combination of ciprofloxacin and vancomycin in human vitreous. Br J Ophthalmol 2004;88:218-222.
24. Raju B, Bali T, Thiagarajan G, Rao V, Das T, Sharma S. Physicochemical properties and antibacterial activity of the precipitate of vancomycin and ceftazidime: implications in the management of endophthalmitis. Retina 2008;28:320-325.
25. Conway MD, Jermak CM, Peyman GA, Swanson HT, Blake DA. Buffering capacity of bovine vitreous. Retina 2008;28:150-153.
26. Hosseini K, Kholodnykh AI, Petrova IY, Esenaliev RO, Hendrikse F, Motamedi M. Monitoring of rabbit cornea response to dehydration stress by optical coherence tomography. Invest Ophthalmol Vis Sci 2004;45:2555-2562.
27. Paque JT, Peyman GA. Intravitreal clindamycin phosphate in the treatment of vitreous infection. Ophthalmic Surg 1974;5:34-39.
28. Homer P, Peyman GA, Koziol J, Sanders DR. Intravitreal injection of vancomycin in experimental staphylococcal endophthalmitis. Acta Ophthalmol (Copenh) 1975;53:311-320.
29. Peyman GA, Vastine DW, Meisels HI. The experimental and clinical use of intravitreal antibiotics to treat bacterial and fungal endophthalmitis. Doc Ophthalmol 1975;39:183-201.
30. Daily MJ, Peyman GA, Fishman G. Intravitreal injection of methicillin for treatment of endophthalmitis. Am J Ophthalmol 1973;76:343-350.
31. May DR, Ericson ES, Peyman GA, Axelrod AJ. Intraocular injection of gentamicin. Single injection therapy of experimental bacterial endophthalmitis. Arch Ophthalmol 1974;91:487-489.
32. Schenk AG, Peyman GA. Lincomycin by direct intravitreal injection in the treatment of experimental bacterial endophthalmitis. Albrecht Von Graefes Arch Klin Exp Ophthalmol 1974;190: 281-291.
33. Bennett TO, Peyman GA. Use of tobramycin in eradicating experimental bacterial endophthalmitis. Albrecht Von Graefes Arch Klin Exp Ophthalmol 1974;191:93-107.
34. Peyman GA, Nelsen P, Bennett TO. Intravitreal injection of kanamycin in experimentally induced endophthalmitis. Can J Ophthalmol 1974;9:322-327.
35. Nelsen P, Peyman GA, Bennett TO. BB-K8: A new aminoglycoside for intravitreal injection in bacterial endophthalmitis. Am J Ophthalmol 1974;78:82-89.
36. Koziol J, Peyman G. Intraocular chloramphenicol and bacterial endophthalmitis. Can J Ophthalmol 1974;9:316-321.
37. Axelrod AJ, Peyman GA, Apple DJ. Toxicity of intravitreal injection of amphotericin B. Am J Ophthalmol 1973;76:578-583.
38. Peyman GA, Herbst R. Bacterial endophthalmitis. Treatment with intraocular injection of gentamicin and dexamethasone. Arch Ophthalmol 1974;91: 416-418.
39. Coats ML, Peyman GA. Intravitreal corticosteroids in the treatment of exogenous fungal endophthalmitis. Retina 1992;12:46-51.
40. Graham RO, Peyman GA. Intravitreal injection of dexamethasone. Treatment of experimentally induced endophthalmitis. Arch Ophthalmol 1974;92:149-154.
41. Jonas B. Intravitreal triamcinolone acetonide: a change in a paradigm. Ophthalmic Res 2006;38: 218-245.
42. Hosseini K, Matsushima D, Johnson J, Widera G, Nyam K, Kim L, et al. Pharmacokinetic study of dexamethasone disodium phosphate using intravitreal, subconjunctival, and intravenous delivery routes in rabbits. J Ocul Pharmacol Ther 2008;24:301-308.
43. Jonas JB, Kamppeter BA, Harder B, Vossmerbaeumer U, Sauder G, Spandau UH. Intravitreal triamcinolone acetonide for diabetic macular edema: a prospective, randomized study. J Ocul Pharmacol Ther 2006;22:200-207.
44. Jonas JB, Schlichtenbrede F. Visual acuity and intraocular pressure after high-dose intravitreal triamcinolone acetonide in selected ocular diseases. Eye (Lond) 2008;22:869-873.
45. Zhang X, Zhu X, Wang D, Xu L, Jonas JB. Lowpower transpupillary thermotherapy combined with intravitreal triamcinolone acetonide for subfoveal choroidal neovascularization. Ophthalmic Res 2007;39:241-242.
46. Bakri SJ, Ekdawi NS. Intravitreal triamcinolone and bevacizumab combination therapy for refractory choroidal neovascularization with retinal angiomatous proliferation. Eye (Lond) 2008;22: 978-980.
47. Cheema RA, Peyman GA, Fang T, Jones A, Lukaris AD, Lim K. Triamcinolone acetonide as an adjuvant in the surgical treatment of retinal detachment with proliferative vitreoretinopathy. Ophthalmic Surg Lasers Imaging 2007;38:365-370.
48. Soheilian M, Ramezani A, Bijanzadeh B, Yaseri M, Ahmadieh H, Dehghan MH, et al. Intravitreal bevacizumab (avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema. Retina 2007;27:1187-1195.
49. Jaffe GJ, McCallum RM, Branchaud B, Skalak C, Butuner Z, Ashton P. Long-term follow-up results of a pilot trial of a fluocinolone acetonide implant to treat posterior uveitis. Ophthalmology 2005;112: 1192-1198.
50. Paris CL, Peyman GA, Gremillion CM Jr, Blinder KJ. Intravitreal dexamethasone following vitreous surgery. Int Ophthalmol 1991;15:173-174.
51. Haller JA, Bandello F, Belfort R Jr, Blumenkranz MS, Gillies M, Heier J, et al. Ozurdex Geneva Study Group. Randomized, sham-controlled trial of dexamethasone intravitreal implant in patients with macular edema due to retinal vein occlusion. Ophthalmology 2010;117:1134-1146.
52. Eyegate Pharmaceuticals Inc. Safety and Efficacy Study of Iontophoresis and Dexamethasone Phosphate to Treat Anterior Uveitis. www.clinicaltrials.gov. First Received June 5, 2008.
53. Hosseini K, Cormier M, Peyman G. Intraocular Jet Injector Device. ARVO Annual Meeting, Fort Lauderdale, Florida, USA. May 2-6, 2010.
54. Zweifel SA, Engelbert M, Khan S, Freund KB. Retrospective review of the efficacy of topical bromfenac (0.09%) as an adjunctive therapy for patients with neovascular age-related macular degeneration. Retina 2009;29:1527-1531.
55. Ista Pharmaceuticals. Preliminary results announced for Xibrom/Lucentis combination therapy for AMD. Review of Ophthalmology 2008;8.
56. Chen E, Benz MS, Fish RH, Brown DM, Wong TP, Kim RY, et al. Use of nepafenac (Nevanac®) in combination with intravitreal anti-VEGF agents in the treatment of recalcitrant exudative macular degeneration requiring monthly injections. Clin Ophthalmol 2010;4:1249-1252.
57. Augustin AJ, Puls S, Offermann I. Triple therapy for choroidal neovascularization due to agerelated macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone. Retina 2007;27:133-140.
58. Liggett PE, Colina J, Chaudhry NA, Tom D, Haffner G. Triple therapy of intravitreal triamcinolone, photodynamic therapy, and pegaptanib sodium for choroidal neovascularization. Am J Ophthalmol 2006;142:1072-1074.
59. Forte R, Bonavolontà P, Benayoun Y, Adenis JP, Robert PY. Intravitreal ranibizumab and bevacizumab in combination with full-fluence verteporfin therapy and dexamethasone for exudative age-related macular degeneration. Ophthalmic Res 2010;45:129-134.